I
Iconic Therapeutics
Clinical stage biopharmaceutical company dedicated to translating scientific insight into breakthrough medicines
About Iconic Therapeutics
Iconic Therapeutics is a biotechnology company focused on developing innovative treatments for serious diseases in the fields of ophthalmology and oncology. Leveraging its deep understanding of tissue factor biology, the company aims to create breakthrough medicines that address inflammation and angiogenesis—key processes involved in disease progression. Iconic Therapeutics serves patients suffering from conditions such as wet age-related macular degeneration (AMD) and various solid tumors. The company operates in the highly competitive biopharmaceutical market and follows a business model that includes research and development, clinical trials, and strategic partnerships. Revenue is generated through licensing agreements, such as those with Zymeworks and Exelixis, and potential future sales of approved therapeutics.
Source: Dealroom company dataAt a glance
- Founded
- 2002
- Headquarters
- South San Francisco, United States
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
ATDC
Lundbeckfonden Ventures
H.I.G. HealthBridge
MPM BioImpact- EVElm Street Ventures
- MBMPM Capital GmbH Beratungsgesellschaft für Biotechnologie-Investitionen
HBM Partners
Series B and later3 investors entered at this stage
Osage University Partners
Cormorant Asset Management
Xeraya Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Iconic Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Iconic Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.